LFP Therapy for Advanced Biliary Tract Cancer
Author Information
Author(s): Kobayashi Kazuma, Tsuji Akihito, Morita Sojiro, Horimi Tadashi, Shirasaka Tetsuhiko, Kanematsu Takashi
Primary Institution: Kochi Municipal Central Hospital
Hypothesis
Can LFP therapy improve outcomes in patients with advanced biliary tract carcinoma?
Conclusion
LFP therapy appears to be a useful modality for the clinical management of advanced biliary tract malignancy.
Supporting Evidence
- The overall response rate was 42.9%.
- The median survival time was 225 days.
- No treatment-related deaths occurred.
- The most common toxicity was anemia, affecting 26.2% of patients.
Takeaway
This study tested a new way to give chemotherapy to patients with a type of cancer that is hard to treat, and it showed some promise.
Methodology
Patients received LFP therapy consisting of continuous infusion of 5-FU and low-dose cisplatin over several cycles, with evaluations based on established criteria.
Limitations
The study was limited by its single-arm design and the lack of a control group.
Participant Demographics
Mean age was 66.5 years, with 54% male participants; 27 had bile duct carcinoma and 15 had gallbladder carcinoma.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% C.I.: 27.7–59.0
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website